Effects of anti-secretory factor (ASF) on irritable bowel syndrome (IBS): A double-blind, randomized study

Scandinavian Journal of Primary Health Care

Volumn 26, Issue 2, 2008, Pages 106-110

  Ekesbo, Rickard ^a,c,d   Nilsson, Peter M ^b   Sjölund, Kristina ^b  

^a Primary Care Centre   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d Dalby Health Centre   (Sweden)

Author keywords

Anti secretory factor; Diet; Family practice; Irritable bowel syndrome

Indexed keywords

ANTISECRETORY FACTOR; NEUROPEPTIDE; PLACEBO; ANTIDIARRHEAL AGENT;

ADULT; AGED; ARTICLE; CEREAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; HUMAN; IRRITABLE COLON; LOOSE FECES; MAJOR CLINICAL STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; ADOLESCENT; BIOSYNTHESIS; BLOOD; DOUBLE BLIND PROCEDURE; FEMALE; MALE; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ANTIDIARRHEALS; CEREALS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; NEUROPEPTIDES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 45749084897     PISSN: 02813432     EISSN: 15027724     Source Type: Journal    
DOI: 10.1080/02813430802005894     Document Type: Article

References (30)

1. Oddsson E, Rask-Madsen J, Krag E. A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea. Scand J Gastroenterol 1978;13:408-16.
2. Agréus L, Svärdsudd K, Nyrén O, et al. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology 1995;109:671-80.
3. Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut 1999;45:1-15.
4. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorder and functional abdominal pain. Gut 1999;45:43-7.
5. Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in post-infective gut dysfunction. Gut 1999;44:400-6.
6. Young E, Stoneham MD, Petruckevitch A, et al. A population study of food intolerance. Lancet 1994;343:1127-30.
7. Svedlund J, Sjödin I, Dotevall G, et al. Upper gastrointestinal and mental symptoms in the irritable bowel syndrome. Scand J Gastroenterol 1985;20:595-601.
8. Simrén M, Abrahamssom H, Björnsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 2001;1:20-2.
9. Sjölund K, Ekman R. Disturbed motilin and cholecystokinin release in the irritable bowel disease. Scand J Gastroenterol 1996;31:1110-4.
10. Jones VA, McLaughlan P, Shorthouse M, et al. Food intolerance: A major factor in the pathogenesis of irritable bowel syndrome. Lancet 1982;2:1115-7.
11. Simrén M, Månsson A, Langkilde AM, et al. Food-related gastrointestinal symptom in the irritable bowel syndrome. Digestion 2001;63:108-15.
12. Dainese R, Galliani EA, De Lazzari F, et al. Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients. Am J Gastroenterol 1999;94:1892-7.
13. Poitras P, Poitras MR, Plourde V, et al. Evolution of visceral sensitivity in patients with irritable bowel syndrome. Dig Dis Sci 2002;47:914-20.
14. Chaudhary NA, Truelove SC. The irritable colon syndrome. QJM 1962;31:307-22.
15. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: Postal survey of patients. BMJ 1997;314:779-82.
16. Lunn PG, Northrop-Clewes CA, Downes RM. Intestinal permeability, mucosal injury, and growth faltering in Gambian infants. Lancet 1991;338:907-10.
17. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: An overview. Gastroenterology 1995;108:1566-81.
18. Collins SM, Piche T, Rampal P. The putative role of inflammation in the irritable bowel syndrome. Gut 2001; 49:743-5.
19. Lönnroth I, Lange S. Purification and characterization of a hormone-like factor which inhibits cholera secretion. FEBS Lett 1984;177:104-8.
20. Lange S, Lönnroth I, Skaldhauge E. Effects of the antisecretory factor in pigs. Pflugers Arch 1987;409:328-32.
21. Lange S, Martinsson K, Lönnroth I, et al. Plasma level of antisecretory factor (ASF) and its relation to post-weaning diarrhoea in piglets. J Vet Med B 1993;40:113-8.
22. Björck S, Bosaeus I, Ek E, et al. Food-induced stimulation of the antisecretory factor improves symptoms in human inflammatory bowel disease. A study of a concept. Gut 2000; 46:824-82.
23. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care 1992;30:473-83.
24. Camilleri M, Choi M-G. Review article: Irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:3-15.
25. Akehurst R, Kaltenthaler E. Review: Treatment of irritable bowel syndrome: A review of randomised controlled trials. Gut 2001;48:272-82.
26. Prior A, Whorwell PJ. Double-blind study of ispaghula in irritable bowel syndrome. Gut 1987;28:1510-3.
27. Snook J, Shepherd HA. Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:511-4.
28. Lucey MR, Clark ML, Lowndes J, et al. Is bran efficacious in irritable bowel syndrome? A double-blind placebo-controlled crossover study. Gut 1987;28:221-5.
29. Spiller RC. Problems and challenges in the design of IBS trials, Part I: A review of the experience from published trials. Am J Gastroenterol 1999;107:915-75.
30. Klein KB. Controlled treatment trials in the irritable bowel syndrome: A critique. Gastroenterology 1988;95:232-41.